2020–21 Serie A2 women's basketball season

DTE Secures $10M Funding Anchored by Industry Leader Novelis and the EIC Fund

Retrieved on: 
Monday, June 19, 2023
Hardware, Automotive Manufacturing, Electronic Design Automation, Alternative Energy, Aerospace, Energy, Manufacturing, Technology, Mining, Minerals, Natural Resources, Other Manufacturing, Steel, Software, Other Energy, Packaging, Engineering, European Innovation Council, Senior, Metal, 2020–21 Serie A2 women's basketball season, Carbon, Corporation, Quality control, Novelis, EIC, EIB, Corporate development, Cryptocurrency, Renewable energy, DTE

The raise includes a distinguished group of investors, with participation by aluminum industry leader Novelis, venture capital firm Metaplanet and the European Innovation Council (EIC) Fund, along with existing investors Chrysalix Venture Capital and Brunnur Ventures.

Key Points: 
  • The raise includes a distinguished group of investors, with participation by aluminum industry leader Novelis, venture capital firm Metaplanet and the European Innovation Council (EIC) Fund, along with existing investors Chrysalix Venture Capital and Brunnur Ventures.
  • DTE's first-in-industry, in-line elemental analysis technology complements and replaces current slow, expensive, and manual methods for process and quality control.
  • "We are delighted to secure this substantial funding round, which is a significant milestone for DTE, validating the transformative potential of our technology," said Karl Matthiasson, CEO & Founder of DTE. "
  • We are delighted and honored to welcome Novelis, Metaplanet and the EIC Fund as new investors on our journey to transform the metals production and manufacturing industries.

Boston Materials Secures $12 Million From Good Growth Capital and Strategic Partners GS Group and PTT Global Chemical

Retrieved on: 
Thursday, November 3, 2022
Environment, Technology, Chemicals, Plastics, Automotive Manufacturing, Aerospace, Sustainability, Manufacturing, Machine Tools, Metalworking & Metallurgy, Hardware, Consumer Electronics, Growth, Dow Jones, 2020–21 Serie A2 women's basketball season, Fortune Global 500, Silent Scope 3, NYSE, Transport, Electronics, CEO, Organization, Adoption, Car, PTT Global Chemical, Engineering, Fiber, Partnership, Technology, GS Group, Carbon, News, Solution, Renewable energy, Textron

The round also includes new strategic investors GS Group and PTT Global Chemical , which will provide important supply chain relationships and unlock customers in new geographical regions.

Key Points: 
  • The round also includes new strategic investors GS Group and PTT Global Chemical , which will provide important supply chain relationships and unlock customers in new geographical regions.
  • Were thrilled to partner with Good Growth Capital, GS Group and PTT Global Chemical, along with our existing investors, as we enter this exciting phase of rapid growth, said Anvesh Gurijala, CEO of Boston Materials.
  • Boston Materials has a differentiated technology with many high-value applications for multiple growth sectors, said David Mendez, Managing Partner at Good Growth Capital.
  • Strategic investors GS Group and PTT Global Chemical will provide important supply chain relationships and access to customers in new regions.

SEngine Precision Medicine closes Series A bringing total financing to $19M enabling continued advancement of personalized cancer treatments

Retrieved on: 
Thursday, July 28, 2022
Knowledge, CLIA, GLOBE, Oncology, Physician, Colon, Series, Drug discovery, Partnership, 3D, Precision, Lung, Fred Hutchinson Cancer Research Center, Technology, 2020–21 Serie A2 women's basketball season, Company, Patient, Science, Robotics, Cancer, Dana–Farber Cancer Institute, Breast, Pharmaceutical industry, Medical imaging, Fine chemical, Vincere

SEngine's CLIA certified PARISTest generates actionable drug sensitivity reports for patients and is applicable to all solid tumors including colon, breast, lung, ovarian and pancreatic cancer.

Key Points: 
  • SEngine's CLIA certified PARISTest generates actionable drug sensitivity reports for patients and is applicable to all solid tumors including colon, breast, lung, ovarian and pancreatic cancer.
  • Investor participation was spurred by the continued momentum of SEngines platform in both drug discovery and clinical diagnostics.
  • SEngine Precision Medicine Inc. is a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived 3D cultures utilizing patient specific tumor cells.
  • SEngine is also pursuing drug discovery via strategic collaborations with biopharmaceutical / pharma companies by deploying its precision oncology platform.